Targeting Vasculogenesis and Interstitial Hypertension in Neurofibromatosis Type1

Information

  • Research Project
  • 7143733
  • ApplicationId
    7143733
  • Core Project Number
    R21HD052126
  • Full Project Number
    1R21HD052126-01A1
  • Serial Number
    52126
  • FOA Number
    PA-03-07
  • Sub Project Id
  • Project Start Date
    8/1/2006 - 17 years ago
  • Project End Date
    7/31/2008 - 15 years ago
  • Program Officer Name
    OSTER-GRANITE, MARY LOU
  • Budget Start Date
    8/1/2006 - 17 years ago
  • Budget End Date
    7/31/2007 - 16 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/24/2006 - 17 years ago
Organizations

Targeting Vasculogenesis and Interstitial Hypertension in Neurofibromatosis Type1

[unreadable] DESCRIPTION (provided by applicant): This is a resubmission of an R21 application. Malignant peripheral nerve sheath tumors (MPNST) are the most common malignant tumor, and the leading cause of mortality in neurofibromatosis type 1 (NF1). Two critical issues in MPNST are neovascularization and high interstitial fluid pressure (IFP). The NG2 proteoglycan, Nf1 haploinsufficiency (Nf1+/-), and accelerated response of neovascular cells to neovascular stimuli are fundamental to both issues. The underlying hypothesis for this proposal is that neovascularization and interstitial fluid hypertension in MPNST can be counteracted by inhibiting both NG2 proteoglycan and Nf1 haploinsufficiency. We propose to establish both vasculogenic and angiogenic pericytes as targets to reduce interstitial fluid pressure and neovascularization in MPNST. Specific Aim 1. Characterize the accelerated contribution of Nf1+/- bone marrow-derived pericytes and endothelial cells to pathological vasculogenesis in NF1 mouse model. We will test whether bone marrow transplantation from wild type mice (Nf1+/+) to Nf1+/- mice reduces vasculogenesis and improves survival in MPNST. Specific Aim 2. Characterize the roles for NG2 in modulation of NF1-driven neovascularization, and in interstitial hypertension. We will determine the extent to which pericyte-NG2 contributes to neovascularization and interstitial hypertension in MPNST. We will test whether the combined inhibition of NG2 and Nf1 haploinsufficiency will maximally inhibit neovascularization due to synergy between NG2, and Nf1 haploinsufficiency. Specific Aim 3. Reveal the role for NG2 in accelerated response of Nf1 haploinsufficient neovascular cells to bFGF. Previous investigations identified bFGF hypersensitivity as a cause of excessive cell proliferation in Nf1 haploinsufficiency. We propose to determine whether there is a bFGF-driven synergistic mechanism linking Nf1 haploinsufficiency and NG2. Specific Aim 4. Identify the origin of high interstitial fluid pressure in MPNST in the NF1 mouse model. We will test whether inhibition of NG2 results in a decrease in interstitial fluid pressure due to decreasing compressive contractile forces within the tumor by decreasing the abnormal number of pericytes and their abnormal contraction properties. [unreadable] [unreadable] [unreadable]

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
  • Activity
    R21
  • Administering IC
    HD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    271784
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    865
  • Ed Inst. Type
  • Funding ICs
    NICHD:271784\
  • Funding Mechanism
  • Study Section
    DT
  • Study Section Name
    Developmental Therapeutics Study Section
  • Organization Name
    LA JOLLA INST FOR MOLECULAR MEDICINE
  • Organization Department
  • Organization DUNS
    941462285
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921213074
  • Organization District
    UNITED STATES